Unknown

Dataset Information

0

The 2.0 A crystal structure of the ERalpha ligand-binding domain complexed with lasofoxifene.

ABSTRACT: Lasofoxifene is a new and potent selective estrogen receptor modulator (SERM). The structural basis of its interaction with the estrogen receptor has been investigated by crystallographic analysis of its complex with the ligand-binding domain of estrogen receptor alpha at a resolution of 2.0 A. As with other SERMs, lasofoxifene diverts the receptor from its agonist-bound conformation by displacing the C-terminal AF-2 helix into the site at which the LXXLL motif of coactivator proteins would otherwise be able to bind. Lasofoxifene achieves this effect by occupying the space normally filled by residue Leu 540, as well as by modulating the conformation of residues of helix 11 (His 524, Leu 525). A well-defined salt bridge between lasofoxifene and Asp 351 suggests that charge neutralization in this region of the receptor may explain the some of the antiestrogenic effects of lasofoxifene. The results suggest general features of ERalpha/SERM recognition, and add a new dimension to efforts to rationalize differences between the biological activity profiles exhibited by these important pharmacological agents.

SUBMITTER: Vajdos FF 

PROVIDER: S-EPMC2206632 | biostudies-literature | 2007 May

REPOSITORIES: biostudies-literature

Json Xml
altmetric image

Publications

The 2.0 A crystal structure of the ERalpha ligand-binding domain complexed with lasofoxifene.

Vajdos Felix F FF   Hoth Lise R LR   Geoghegan Kieran F KF   Simons Samuel P SP   LeMotte Peter K PK   Danley Dennis E DE   Ammirati Mark J MJ   Pandit Jayvardhan J  

Protein science : a publication of the Protein Society 20070501 5

Lasofoxifene is a new and potent selective estrogen receptor modulator (SERM). The structural basis of its interaction with the estrogen receptor has been investigated by crystallographic analysis of its complex with the ligand-binding domain of estrogen receptor alpha at a resolution of 2.0 A. As with other SERMs, lasofoxifene diverts the receptor from its agonist-bound conformation by displacing the C-terminal AF-2 helix into the site at which the LXXLL motif of coactivator proteins would othe  ...[more]

Similar Datasets

Unknown Crystal structure of human GGA1 GAT domain complexed with the GAT-binding domain of Rabaptin5.
| S-EPMC524345 | biostudies-literature
Unknown Crystal structure of mouse coronavirus receptor-binding domain complexed with its murine receptor.
| S-EPMC3127895 | biostudies-literature
Unknown Crystal structure of the T877A human androgen receptor ligand-binding domain complexed to cyproterone acetate provides insight for ligand-induced conformational changes and structure-based drug design.
| S-EPMC2080778 | biostudies-literature
Unknown Novel Mode of Antagonist Binding in NMDA Receptors Revealed by the Crystal Structure of the GluN1-GluN2A Ligand-Binding Domain Complexed to NVP-AAM077.
| S-EPMC5452055 | biostudies-literature
Unknown Crystal structure of NL63 respiratory coronavirus receptor-binding domain complexed with its human receptor.
| S-EPMC2785276 | biostudies-literature
Unknown Crystal structure of the cysteine-rich domain of mannose receptor complexed with a sulfated carbohydrate ligand.
| S-EPMC2193177 | biostudies-literature
Unknown Crystal structure of the ligand binding domain of netrin G2.
| S-EPMC4535689 | biostudies-literature
Unknown Comparison of crystal structures of human androgen receptor ligand-binding domain complexed with various agonists reveals molecular determinants responsible for binding affinity.
| S-EPMC2242507 | biostudies-literature
Unknown Crystal structure and ligand binding of the MID domain of a eukaryotic Argonaute protein.
| S-EPMC2897117 | biostudies-literature
Unknown Crystal structure of the Mp1p ligand binding domain 2 reveals its function as a fatty acid-binding protein.
| S-EPMC2838340 | biostudies-literature